A nationwide recall has been issued for four lots of Cetirizine Hydrochloride Tablets USP 5 mg after the manufacturer discovered the allergy medication may be contaminated with ranitidine.
Unique Pharmaceutical Laboratories announced the voluntary recall after a pharmacy technician noticed discolored tablets with red spots while dispensing the medication. An investigation determined the product could have been cross-contaminated with ranitidine.
The recalled medication is distributed by Rising Pharma Holdings Inc. and comes in 100-tablet HDPE bottles with NDC number 16571-401-10. The affected lot numbers are GY825029, GY825030, GY825031, and GY825032, all with expiration dates of October 2028.
The medication is used as an antihistamine to treat allergy symptoms. While no adverse events have been reported, the company said people who are allergic or hypersensitive to ranitidine could experience serious reactions, including anaphylaxis, difficulty breathing or swallowing, swelling of the face or throat, hives, low blood pressure, or loss of consciousness.
The recalled product was distributed nationwide to wholesalers and retailers. Consumers who have the affected medication should stop using it and contact their healthcare provider if they experience any adverse effects.
View full recall here.
Subscribe to our FREE Newsletter
